eCite Digital Repository

A double-blind, placebo controlled study of the effect of the specific histamine H-1-receptor antagonist, terfenadine, in chronic severe asthma

Citation

Wood-Baker, R and Smith, R and Holgate, ST, A double-blind, placebo controlled study of the effect of the specific histamine H-1-receptor antagonist, terfenadine, in chronic severe asthma, British Journal of Clinical Pharmacology, 39, (6) pp. 671-675. ISSN 0306-5251 (1995) [Refereed Article]

DOI: doi:10.1111/j.1365-2125.1995.tb05727.x

Abstract

1. The characteristic changes seen in asthma are widely regarded as being caused by local mediator release in the airways, with histamine the first putative mediator in asthma to be identified. 2. We performed a double‐blind, randomised, placebo‐controlled crossover trial of the effect of 4 weeks treatment with terfenadine 120 mg twice daily in chronic severe asthma. 3. Forty‐two subjects (20 male and 22 female) completed the 10 week study. 4. Terfenadine had no significant treatment effect on the primary efficacy variables measured. Mean (95% CI) measurements for terfenadine vs placebo treatment periods were 1.5 vs 1.5 (‐0.3, 0.3) l for FEV1, 259 vs 260 (‐42, 40) l min‐1 for morning PEF and 0.8 vs 0.8 (‐0.3, 0.3) for global symptom scores. 5. Bronchodilator use and sleep disturbance, the secondary efficacy variables studied, showed an improvement during terfenadine treatment but this only reached statistical significance for the number of times subjects awoke from sleep (P = 0.04). 6. There was a similar frequency of minor adverse effects reported during placebo (13.6%) and terfenadine (16.7%) treatments. 7. Addition of the potent and specific histamine H1‐receptor antagonist terfenadine to maintenance asthma treatment had no significant therapeutic benefit in this group of chronic severe asthmatics. Copyright © 1995, Wiley Blackwell. All rights reserved

Item Details

Item Type:Refereed Article
Research Division:Medical and Health Sciences
Research Group:Pharmacology and Pharmaceutical Sciences
Research Field:Clinical Pharmacology and Therapeutics
Objective Division:Health
Objective Group:Other Health
Objective Field:Health not elsewhere classified
Author:Wood-Baker, R (Professor Richard Wood-Baker)
ID Code:6274
Year Published:1995
Web of Science® Times Cited:12
Deposited By:Clinical Sciences
Deposited On:1995-08-01
Last Modified:2011-08-25
Downloads:0

Repository Staff Only: item control page